Edition:
United Kingdom

electroCore, Inc. (ECOR.OQ)

ECOR.OQ on NASDAQ Stock Exchange Global Select Market

6.40USD
18 Apr 2019
Change (% chg)

$0.64 (+11.11%)
Prev Close
$5.76
Open
$5.77
Day's High
$6.40
Day's Low
$5.77
Volume
14,812
Avg. Vol
40,275
52-wk High
$20.25
52-wk Low
$4.18

Summary

Name Age Since Current Position

Joseph Errico

2016 Chairman of the Board, Co-Founder, Principal Investor and Chief Science & Strategy Officer

Carrie Cox

Chairman of the Board

Francis Amato

2016 Chief Executive Officer

Steve Mendez

2016 Co-Founder, Chief Technical Officer

Thomas Errico

Co-Founder, Board Member and Principal Investor

Brian Posner

56 2019 Chief Financial Officer

Eric Liebler

54 Senior Vice President - Neurology

Ardelle Ferris

Vice President-Market Access

Mike Romaniw

Vice President, Quality Assurance & Regulatory Affairs

Bruce Simon

Vice President,Research

Dan Duhart

Chief Commercial Officer

Anthony Fiorino

2019 Chief Medical Officer

Michael Atieh

64 Director

Nick Colucci

Director

Trevor Moody

Director

Stephen Ondra

Director

James Tullis

71 Director

Biographies

Name Description

Joseph Errico

Mr. J.P. Errico is the Chairman of the Board, Co-Founder, Principal Investor and Chief Science & Strategy Officer of the Company. JP received his undergraduate degree in aeronautical engineering from the Massachusetts Institute of Technology, and worked at the Air Force National Laboratory, Lincoln Laboratories. He holds both law and mechanical/materials engineering graduate degrees from Duke University. JP trained as a patent attorney in New York, and is the author of a treatise on international intellectual property law. Along with fellow investor and Board Member, Dr. Thomas Errico, Mr. Errico has founded a number of medical device companies, including Fastenetix, K2 Medical, AD-4 Pharma, E2, and SpineCore. Products conceived by these companies have generated more than $8 billion in sales to date. He served as the CEO of SpineCore from the inception of the company through to its sale to Stryker in July 2004. JP is a named inventor on more than 125 issued US patents, and is a named inventor on more than 100 pending US applications. Additional patents and patent applications outside the US on which he is a named inventor number greater than 200. In addition to his current role as CSSO, he continues also to make significant inventive contributions in all aspects of the company’s key patent portfolios, along with the clinical and market validations of the company’s products and their indications.

Carrie Cox

Ms. Carrie S Cox is Chairman of the Board. Ms. Carrie S. Cox is Executive Chairman and former Chief Executive Officer of Humacyte, Inc. She joined Humacyte in 2010 and previously served as Executive Vice President and President, Global Pharmaceuticals, at Schering-Plough Corporation from 2003 until its merger with Merck & Co., Inc. in November 2009. At Merck & Co., Inc., she was responsible for the company’s global prescription pharmaceutical business, which generated approximately $16 billion in annual sales. Carrie held a similar role as President, Global Prescription Business at Pharmacia Corporation, as well as Senior Vice President of Global Business Management at Pharmacia & Upjohn (the predecessor company to Pharmacia), and Vice President of Women’s Healthcare at Wyeth-Ayerst. Carrie spent her early career at Sandoz Pharmaceuticals in a variety of commercial roles of increasing responsibility. She currently serves on the Boards of Directors of Texas Instruments, Cardinal Health, and Celgene, and she has served as Lead Director for Texas Instruments. Carrie has been named six times to Fortune’s list of the “50 Most Powerful Women in Business.” Her work has been featured in Harvard Business Review and in The New York Times’ bestseller, The Profit Zone. She received her Bachelor of Science from the Massachusetts College of Pharmacy in 1981.

Francis Amato

Mr. Francis R. Amato is the Chief Executive Officer of the Company. Prior to joining electroCore Frank spent 22 years within the pharmaceutical industry. Most recently as Vice President of the Specialty Commercial Operations Group, Global Human Health at Merck. Frank has extensive commercial experience previous roles include: Executive Director, Global Business Operations, Schering-Plough, Business Unit Lead, Oncology, Ligand Pharmaceuticals. National Sales Director, Specialty Managed Markets, Pfizer Inc. National Sales Director Hospitals, Pharmacia Corporation. Frank joined The Upjohn Company in 1990 as a sales representative in NYC. Prior to joining the pharmaceutical industry he was a Infantry Medic in the 82nd Airborne Division of the United States Army. Frank received his Executive MBA from Pepperdine University Graziadio School of Management in 2005 and undergraduate degree in Political Science from St. John’s University in 1990.

Steve Mendez

Mr. Steve Mendez is the Co-Founder, Chief Technical Officer of the Company. Steve is a Research and Development executive with 28 years experience driving all phases of product life cycle from concept/patents and design to manufacturing and sales/field support. Previously Vice President of Development with the EBI division of Biomet, Steve was responsible for electronic, bracing, and softgood products in addition to overseeing the development of external and implantable electrical/thermal therapy medical devices. He also established and managed electronic production/test/repair departments at EBI and previous employers. Steve obtained an MSEE from Rensselaer Polytechnic Institute and a BSEE and BA Biology from Lehigh University.

Thomas Errico

Dr. Thomas J. Errico is the Co-Founder, Board Member and Principal Investor of the Company. Dr. Errico is a graduate of the New Jersey College of Medicine. After completing a residency in orthopedic surgery, he completed a yearlong fellowship in spinal surgery in Toronto with Dr. John Kostuik. After his fellowship, Dr. Errico accepted a joint position in the faculties of both Orthopedic Surgery and Neurosurgery at the New York University Medical School. Now a tenured professor in both departments, Dr. Errico is serving as the Chief of Spine Service for both New York University and the Hospital for Joint Diseases. He is an original member of the North American Spine Society, and served as that society’s President for 2004-5. Along with J.P. Errico, he founded several medical device companies, and according to the MedicineLodge 2001 Spinal Implant Intellectual Property Report, is the most prolific surgeon inventor in the field of spine orthopedics. Dr. Errico has been identified as one of the 10 best orthopedic surgeons in the United States. Dr. Errico served on the Board of Directors of SpineCore from its inception to sale. It is expected that Dr. Errico will serve as a primary contributor and advisor to electroCore for the development of the company’s products and their indications.

Brian Posner

Mr. Brian M. Posner is Chief Financial Officer of the company. Mr. Posner joins electroCore from Cellectar Biosciences, where he served as chief financial officer since April 2018. Prior to Cellectar, he served in chief financial officer roles at Alliqua BioMedical, Ocean Power Technologies and Power Medical Interventions. Earlier, Mr. Posner spent nine years at Pharmacopeia, where he rose from director of finance to chief financial officer before the company was acquired by Ligand Pharmaceuticals. Prior to Pharmacopeia, he was chief financial officer and vice president of operations at Photosynthetic Harvest, a start-up biotechnology company, and regional chief financial officer at Omnicare. Mr. Posner began his career as an audit supervisor at Coopers & Lybrand which was subsequently merged to form PricewaterhouseCoopers.

Eric Liebler

Mr.Eric J Liebler is Senior Vice President - Neurology of company.Eric brings more than 20 years of neurological industry and association experience to electroCore. In 2009, he co-founded Nautilus Neurosciences, a neurology-focused specialty pharmaceutical company focused on identifying and developing drugs benefiting those affected by neurological disorders, and brought to market Cambia® for the treatment of acute migraine. At Nautilus, Eric was involved in all facets of the company’s organization and early success, including initial funding, product commercialization, and sales and marketing. Eric has held leadership positions at Elan, Amarin, Enzon Pharmaceuticals, Questcor Pharmaceuticals, and Pharmacopeia. He founded Nisola LLC, an advocacy and business strategy consulting firm focused on serving clients in the field of neurology, and sat on the Board of Trustees of the American Academy of Neurology Foundation (now the American Brain Foundation) for more than a decade. Eric began his career at Athena Neurosciences, a pioneer in the development of neurology drugs, after graduating with honors from Tufts University.

Ardelle Ferris

Ms.Ardelle Ferris is Vice President-Market Access of company. responsible for shaping electroCore's commercial PBM and Health Plan Payer Strategy and executing on the company's vision of growing payer coverage and reimbursement for gamma Core in the United States. Ardelle brings over 30 years of experience in national account management with PBMs and commercial health plans, and has held various market access management positions throughout her career. She has developed specialized expertise in achieving national sales goals set for several market segments, and providing strategic counsel to successfully ensure formulary uptake and profitable access with national account customers such as United Healthcare, Humana and Magellan Rx Management. She also has extensive experience navigating policy as related to Medicare Part D and Medicaid. Ardelle most recently held the position as Head of National Accounts at Intarcia Therapeutics, and has served in national and senior account manager roles at Pfizer and Vertex Pharmaceuticals. During her tenure at Pfizer, she was inducted into the Pfizer Hall of Fame for her contributions. Prior to joining the pharmaceutical industry, Ardelle worked in a surgical ICU as a registered nurse. She holds a Bachelor of Arts in Nursing from Jamestown University and continues to hold licensure in Minnesota.

Mike Romaniw

Mr.Mike Romaniw Vice President, Quality Assurance & Regulatory Affairs of company.Mike is a Quality Assurance and Regulatory Compliance executive with over 40 years of experience in the medical device industry, including manufacturing, design and development, and quality management. Mike has led the successful development and deployment of quality management systems established to meet FDA, as well as international, regulatory requirements for several organizations. Prior to joining electroCore, Mike served as the Director of Quality Assurance and Regulatory Compliance at Blackstone Medical, Inc, where he was responsible for product quality control, quality engineering, supplier management, and product complaint handling, as well as the management of field actions and recalls.

Bruce Simon

Mr.Bruce J Simon is vice president of the company.Bruce has broad expertise in research, having spent the last 16 years prior to joining electroCore as Senior Director of Research at the EBI division of Biomet, Inc, where he directed research on the effects of electric and electromagnetic fields on bone, cartilage, and soft tissue repair. He has more than 60 peer-reviewed publications and 50 issued or pending patents.Bruce obtained a Bachelor of Science degree in Physics from the Massachusetts Institute of Technology and a PhD in Physiology and Biophysics from the University of Iowa. After completing his PhD, he spent several years as a Research Assistant Professor at the University of Maryland and then as an Assistant Professor at the University of Texas. His research focused on various aspects of electrophysiology, including excitation-contraction coupling in muscle and biophysical modeling.

Dan Duhart

Mr. Dan Duhart is Chief Commercial Officer in the company. Dan has served in senior sales and marketing roles for more than 20 years. Prior to joining electroCore, Dan was Vice President for Business Development with Touchpoint Solutions, preceded by SVP Client Services and Business Development for VMS BioMarketing, and followed by Amylin Pharmaceuticals where, as Senior Director of Sales and Marketing, he developed, recruited, and led diabetes-specialty sales teams accountable for the successful commercial launches of BYDUREON®, BYETTA®, and SYMLIN®. Dan has also held leadership roles with Novartis, Pharmacia Corporation, and Schering-Plough. Dan received his Bachelor of Science in Business Administration, Finance, from California State University, Northridge.

Anthony Fiorino

Dr. Anthony Fiorino M.D. Ph.D. is Chief Medical Officer of the company. Dr. Fiorino joins electroCore from Immune Pharma, where he served as interim chief executive officer since August 2018. He joined Immune as chief medical officer and chief operating officer in August 2017 from Triumvira Immunologics, an immuno-oncology company developing a novel engineered T cell platform, where he served as president and chief executive officer. Prior to joining Triumvira, Dr. Fiorino was the chief executive officer of BrainStorm Cell Therapeutics (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases. Prior to joining BrainStorm, he was the founder, president and chief executive officer of EnzymeRx, where he led the acquisition of a late-stage pre-clinical biologic and the development of the compound through Phase 2 clinical trials and its subsequent sale to 3SBio. Before founding EnzymeRx, Dr. Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup and Pequot Capital. Dr. Fiorino earned an M.D. and a Ph.D. from the Albert Einstein College of Medicine and a bachelor of science degree from the Massachusetts Institute of Technology.

Michael Atieh

Mr.Michael G Atieh is Director of company. After starting his career with Ernst and Young where he became an Audit Manager, Mike spent the majority of his career in the biotechnology and pharmaceutical industries. Prior to his retirement in 2016, Mike was Executive Vice President, Chief Financial and Business Officer at Ophthotech, Inc. (Nasdaq: OPHT), a public biotechnology company. His previous experience included roles as Executive Chairman of Eyetech Inc., a private specialty pharmaceutical company; Executive Vice President and Chief Financial Officer of OSI Pharmaceuticals (Nasdaq: OSIP), a public biotechnology company; and Senior Vice President and Chief Financial Officer of Dendrite International, Inc. (Nasdaq: DRTE), a pharmaceutical services company. In the 1990s, Mike held various senior corporate positions, including Treasurer at Merck & Co., Inc. (NYSE: MRK) and Vice President of US Human Health, a division of Merck.Mike currently serves on the Board of Directors of Chubb Limited (NYSE: CB) where he is a member of the Risk and Finance Committee and previously served as the Chair of the Audit Committee from 2012 until May 2018. His previous public company board experience was with Theravance Biopharma (Nasdaq:TBPH) and OSI Pharmaceuticals, where he also served as Chair of the Audit Committee. Mike graduated from Upsala College with a Bachelor of Science in Accounting and Finance.

Nick Colucci

Mr. Nick Colucci is Director of company. Nick serves as Chairman, Publicis Health and Chief Operating Officer, Publicis Communications North America. He joined Publicis Health in 2000 as President, then became Chief Operating Officer before rising to CEO in 2007. Nick’s experience spans both client and agency sides of communications businesses. Previously, Nick served as Vice President of Marketing & Sales at EyeSys Technologies and Marketing Director at Roche. In addition to his current role at Publicis Health, Nick serves on the Board of the American Heart Association of New York. He is a passionate and outspoken advocate for inclusion and gender parity. His leadership and continuous efforts have resulted in numerous accolades, including MM&M’s 50 Health Influencers, PharmaVOICE’s “100 Most Inspiring People," and the Superhero of Heart and Stroke Award from the American Heart Association. Nick earned a Bachelor of Science in Neuroscience from the University of Rochester and a Master of Business Administration from Loyola University Maryland.

Trevor Moody

Mr. Trevor Moody is Director of company. Mr. Trevor is a Partner at M.H. Carnegie & Co, an Australian private equity and venture capital firm. He is also President of TM Strategic Advisors LLC, a management consultancy serving the boards, investors, and senior management of both emerging and established medical technology companies. Trevor brings significant experience, with over 25 years in the development, commercialization, and funding of innovative growth-oriented medical technologies. He was previously a General Partner at Frazier Healthcare Ventures, a leading healthcare venture capital and private equity investment firm with over $3 billion under management. Trevor co-led the medical device team at Frazier and became known as an active and well-regarded investor. In addition to several private boards, Trevor is the previous Board Chair of the Center for Infectious Disease Research, one of the largest independent non-profit research institutes focused on diseases of the developing world. Trevor graduated from the Massachusetts Institute of Technology with a Master of Science in Management (Sloan School) and the University of Southern Queensland, Australia, with a Bachelor of Engineering. Trained as a biomedical engineer with an electrical focus, Trevor held product development and product marketing roles at Telectronics Pacing Systems and Ventritex, both in the cardiac rhythm management market.

Stephen Ondra

Dr Stephen L Ondra is Director of company.Dr. Ondra is Chief Executive Officer of North Star Healthcare Consulting, a healthcare technology consulting company that he founded in 2017. From 2013 to 2016, Dr. Ondra served as Senior Vice President and Chief Medical Officer of Health Care Service Corporation, the largest customer-owned health insurance company in the United States. Previously, Dr. Ondra served as Senior Vice President and Chief Medical Officer of Northwestern Memorial Hospital. In 2009, Dr. Ondra was appointed by President Obama as Senior Policy Advisor for Health Affairs of the US Department of Veterans Affairs, assigned to the Executive Office of the President of the United States from 2010 to 2012. At the White House he held several positions, including Co-Chair of the National Science and Technology Council for Health Information Technology. A board-certified neurosurgeon, Dr. Ondra was a Professor of Neurosurgery and Residency Program Director at Northwestern University’s Feinberg School of Medicine from 1996 to 2009. Dr. Ondra graduated from Rush Medical College in Chicago with a Doctor of Medicine, completing residency training in neurosurgery at the Walter Reed Army Medical Center in Washington, DC. As a US Army physician, Dr. Ondra served with distinction in Operations Desert Shield and Desert Storm and was awarded Bronze Star and Army Commendation Medals.

James Tullis

Mr.James Tullis is Director of company.Mr.James Tullis founded Tullis Health Investors (THI or Tullis-Dickerson & Co, Inc) in 1986 and has a career in healthcare investing that spans more than 4 decades. As Managing Partner or CEO, Jim has led 10 THI healthcare-focused venture capital/growth equity funds, which have in turn been lead investors in successful biotech, pharmaceutical, medical device, medical service, and healthcare IT companies including PSS World Medical, Adams Pharmaceuticals, Genoptix, Synageva, Biorex, Atritech, Impulse Monitoring, Vidacare, and others. Prior to establishing Tullis Health Investors in 1986, Jim was a Senior Vice President of E.F. Hutton and a Principal at Morgan Stanley, where he led healthcare investment research and, later, healthcare investment banking. During his tenure at Morgan Stanley, he received recognition 14 times on the Institutional Investor All-Star list of Wall Street’s top securities analysts. He was twice named #1 Drug Analyst and was featured on the Wall Street Week television program. Jim is a graduate of Stanford University and earned a Master of Business Administration from Harvard Business School. He currently sits on the Boards of the Lord Abbett family of mutual funds (where he is Chairman), Crane Co., Exagen Diagnostics, SafeOp (where he is Chairman), LivHOME, Inc, and SupplyPro, Inc. Jim is also a Board Member of the National Parks Conservation Association.